APO Research
Talk to an analyst

APO RESEARCH · REPORT

Trastuzumab Biosimilar

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Trastuzumab Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025196 pages

Choose your research edition.

Industry ResearchTrastuzumab Biosimilar Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Trastuzumab Biosimilar Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Trastuzumab Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Trastuzumab Biosimilar Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Trastuzumab Biosimilar Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Trastuzumab Biosimilar market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Trastuzumab Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Trastuzumab Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Trastuzumab Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Trastuzumab Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Trastuzumab Biosimilar include Mundipharma, Samsung Bioepis, Amgen Inc., Biocon Limited, Henlius, Pfizer Inc, Genentech, Merck & Co. and Celltrion, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Trastuzumab Biosimilar market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Trastuzumab Biosimilar and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Trastuzumab Biosimilar sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Trastuzumab Biosimilar market size, projected growth trends, production technologies, key applications, and end-use industries.

Trastuzumab Biosimilar Segment by Company

Mundipharma

Samsung Bioepis

Amgen Inc.

Biocon Limited

Henlius

Pfizer Inc

Genentech

Merck & Co.

Celltrion

Teva Pharmaceutical

Trastuzumab Biosimilar Segment by Type

Adjuvant Breast Cancer

Metastatic Breast Cancer

Metastatic Gastric Cancer

Others

Trastuzumab Biosimilar Segment by Application

Hospital Pharmacy

Online Pharmacy

Trastuzumab Biosimilar Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Trastuzumab Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Trastuzumab Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Trastuzumab Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Trastuzumab Biosimilar market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Trastuzumab Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Trastuzumab Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Trastuzumab Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Trastuzumab Biosimilar Industry Trends Table 2. Trastuzumab Biosimilar Industry Drivers Table 3. Trastuzumab Biosimilar Industry Opportunities and Challenges Table 4. Trastuzumab Biosimilar Industry Restraints Table 5. Global Trastuzumab Biosimilar Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Trastuzumab Biosimilar Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Trastuzumab Biosimilar Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Trastuzumab Biosimilar Sales Market Share by Manufacturers Table 9. Global Trastuzumab Biosimilar Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Trastuzumab Biosimilar Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Trastuzumab Biosimilar Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Trastuzumab Biosimilar Manufacturers, Product Type & Application Table 13. Global Trastuzumab Biosimilar Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Trastuzumab Biosimilar by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Adjuvant Breast Cancer Table 17. Major Manufacturers of Metastatic Breast Cancer Table 18. Major Manufacturers of Metastatic Gastric Cancer Table 19. Major Manufacturers of Others Table 20. Global Trastuzumab Biosimilar Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Trastuzumab Biosimilar Sales by Type (2021-2026) & (K Units) Table 22. Global Trastuzumab Biosimilar Sales by Type (2027-2032) & (K Units) Table 23. Global Trastuzumab Biosimilar Sales Market Share by Type (2021-2026) Table 24. Global Trastuzumab Biosimilar Sales Market Share by Type (2027-2032) Table 25. Global Trastuzumab Biosimilar Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Trastuzumab Biosimilar Revenue by Type (2021-2026) & (K Units) Table 27. Global Trastuzumab Biosimilar Revenue by Type (2027-2032) & (K Units) Table 28. Global Trastuzumab Biosimilar Revenue Market Share by Type (2021-2026) Table 29. Global Trastuzumab Biosimilar Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Pharmacy Table 31. Major Manufacturers of Online Pharmacy Table 32. Global Trastuzumab Biosimilar Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Trastuzumab Biosimilar Sales by Application (2021-2026) & (K Units) Table 34. Global Trastuzumab Biosimilar Sales by Application (2027-2032) & (K Units) Table 35. Global Trastuzumab Biosimilar Sales Market Share by Application (2021-2026) Table 36. Global Trastuzumab Biosimilar Sales Market Share by Application (2027-2032) Table 37. Global Trastuzumab Biosimilar Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Trastuzumab Biosimilar Revenue by Application (2021-2026) & (K Units) Table 39. Global Trastuzumab Biosimilar Revenue by Application (2027-2032) & (K Units) Table 40. Global Trastuzumab Biosimilar Revenue Market Share by Application (2021-2026) Table 41. Global Trastuzumab Biosimilar Revenue Market Share by Application (2027-2032) Table 42. Global Trastuzumab Biosimilar Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Trastuzumab Biosimilar Sales by Region (2021-2026) & (K Units) Table 44. Global Trastuzumab Biosimilar Sales Market Share by Region (2021-2026) Table 45. Global Trastuzumab Biosimilar Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Trastuzumab Biosimilar Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Trastuzumab Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Trastuzumab Biosimilar Sales by Country (2021-2026) & (K Units) Table 49. North America Trastuzumab Biosimilar Sales by Country (2027-2032) & (K Units) Table 50. Europe Trastuzumab Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Trastuzumab Biosimilar Sales by Country (2021-2026) & (K Units) Table 52. Europe Trastuzumab Biosimilar Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Trastuzumab Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Trastuzumab Biosimilar Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Trastuzumab Biosimilar Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Trastuzumab Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Trastuzumab Biosimilar Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Trastuzumab Biosimilar Sales by Country (2027-2032) & (K Units) Table 59. Global Trastuzumab Biosimilar Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Trastuzumab Biosimilar Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Trastuzumab Biosimilar Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Trastuzumab Biosimilar Revenue Market Share by Region (2021-2026) Table 63. Global Trastuzumab Biosimilar Revenue Market Share by Region (2027-2032) Table 64. Mundipharma Company Information Table 65. Mundipharma Business Overview Table 66. Mundipharma Trastuzumab Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Mundipharma Trastuzumab Biosimilar Product Portfolio Table 68. Mundipharma Recent Development Table 69. Samsung Bioepis Company Information Table 70. Samsung Bioepis Business Overview Table 71. Samsung Bioepis Trastuzumab Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Samsung Bioepis Trastuzumab Biosimilar Product Portfolio Table 73. Samsung Bioepis Recent Development Table 74. Amgen Inc. Company Information Table 75. Amgen Inc. Business Overview Table 76. Amgen Inc. Trastuzumab Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Amgen Inc. Trastuzumab Biosimilar Product Portfolio Table 78. Amgen Inc. Recent Development Table 79. Biocon Limited Company Information Table 80. Biocon Limited Business Overview Table 81. Biocon Limited Trastuzumab Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Biocon Limited Trastuzumab Biosimilar Product Portfolio Table 83. Biocon Limited Recent Development Table 84. Henlius Company Information Table 85. Henlius Business Overview Table 86. Henlius Trastuzumab Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Henlius Trastuzumab Biosimilar Product Portfolio Table 88. Henlius Recent Development Table 89. Pfizer Inc Company Information Table 90. Pfizer Inc Business Overview Table 91. Pfizer Inc Trastuzumab Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Pfizer Inc Trastuzumab Biosimilar Product Portfolio Table 93. Pfizer Inc Recent Development Table 94. Genentech Company Information Table 95. Genentech Business Overview Table 96. Genentech Trastuzumab Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Genentech Trastuzumab Biosimilar Product Portfolio Table 98. Genentech Recent Development Table 99. Merck & Co. Company Information Table 100. Merck & Co. Business Overview Table 101. Merck & Co. Trastuzumab Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Merck & Co. Trastuzumab Biosimilar Product Portfolio Table 103. Merck & Co. Recent Development Table 104. Celltrion Company Information Table 105. Celltrion Business Overview Table 106. Celltrion Trastuzumab Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Celltrion Trastuzumab Biosimilar Product Portfolio Table 108. Celltrion Recent Development Table 109. Teva Pharmaceutical Company Information Table 110. Teva Pharmaceutical Business Overview Table 111. Teva Pharmaceutical Trastuzumab Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Teva Pharmaceutical Trastuzumab Biosimilar Product Portfolio Table 113. Teva Pharmaceutical Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Trastuzumab Biosimilar Distributors List Table 117. Trastuzumab Biosimilar Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Trastuzumab Biosimilar Product Image Figure 2. Global Trastuzumab Biosimilar Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Trastuzumab Biosimilar Market Size (2021-2032) & (US$ Million) Figure 4. Global Trastuzumab Biosimilar Sales (2021-2032) & (K Units) Figure 5. Global Trastuzumab Biosimilar Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Trastuzumab Biosimilar Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Adjuvant Breast Cancer Image Figure 9. Metastatic Breast Cancer Image Figure 10. Metastatic Gastric Cancer Image Figure 11. Others Image Figure 12. Global Trastuzumab Biosimilar Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Trastuzumab Biosimilar Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Trastuzumab Biosimilar Sales Market Share by Type (2021-2032) Figure 15. Global Trastuzumab Biosimilar Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Trastuzumab Biosimilar Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Trastuzumab Biosimilar Revenue Market Share by Type (2021-2032) Figure 18. Hospital Pharmacy Image Figure 19. Online Pharmacy Image Figure 20. Global Trastuzumab Biosimilar Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Trastuzumab Biosimilar Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Trastuzumab Biosimilar Sales Market Share by Application (2021-2032) Figure 23. Global Trastuzumab Biosimilar Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Trastuzumab Biosimilar Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Trastuzumab Biosimilar Revenue Market Share by Application (2021-2032) Figure 26. North America Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Trastuzumab Biosimilar Sales Market Share by Country (2021-2032) Figure 28. U.S. Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Trastuzumab Biosimilar Sales Market Share by Country (2021-2032) Figure 33. Germany Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Trastuzumab Biosimilar Sales Market Share by Country (2021-2032) Figure 40. China Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Trastuzumab Biosimilar Sales Market Share by Country (2021-2032) Figure 48. Brazil Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Trastuzumab Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Trastuzumab Biosimilar Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Trastuzumab Biosimilar Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Trastuzumab Biosimilar Revenue (2021-2032) & (US$ Million) Figure 59. North America Trastuzumab Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Trastuzumab Biosimilar Revenue (2021-2032) & (US$ Million) Figure 61. Europe Trastuzumab Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Trastuzumab Biosimilar Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Trastuzumab Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Trastuzumab Biosimilar Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Trastuzumab Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Trastuzumab Biosimilar Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Trastuzumab Biosimilar Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Adjuvant Breast Cancer
  • Metastatic Breast Cancer
  • Metastatic Gastric Cancer
  • Others
Applications
  • Hospital Pharmacy
  • Online Pharmacy
Companies covered
  • Mundipharma
  • Samsung Bioepis
  • Amgen Inc.
  • Biocon Limited
  • Henlius
  • Pfizer Inc
  • Genentech
  • Merck & Co.
  • Celltrion
  • Teva Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Trastuzumab Biosimilar Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Trastuzumab Biosimilar Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Trastuzumab Biosimilar Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Trastuzumab Biosimilar Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Trastuzumab Biosimilar Market Dynamics
  1. 2.1 Trastuzumab Biosimilar Industry Trends
  2. 2.2 Trastuzumab Biosimilar Industry Drivers
  3. 2.3 Trastuzumab Biosimilar Industry Opportunities and Challenges
  4. 2.4 Trastuzumab Biosimilar Industry Restraints
3 Trastuzumab Biosimilar Market by Manufacturers
  1. 3.1 Global Trastuzumab Biosimilar Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Trastuzumab Biosimilar Sales by Manufacturers (2021-2026)
  3. 3.3 Global Trastuzumab Biosimilar Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Trastuzumab Biosimilar Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Trastuzumab Biosimilar Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Trastuzumab Biosimilar Manufacturers, Product Type & Application
  7. 3.7 Global Trastuzumab Biosimilar Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Trastuzumab Biosimilar Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Trastuzumab Biosimilar Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Trastuzumab Biosimilar Tier 1, Tier 2, and Tier 3
4 Trastuzumab Biosimilar Market by Type
  1. 4.1 Trastuzumab Biosimilar Type Introduction
  2. 4.1.1 Adjuvant Breast Cancer
  3. 4.1.2 Metastatic Breast Cancer
  4. 4.1.3 Metastatic Gastric Cancer
  5. 4.1.4 Others
  6. 4.2 Global Trastuzumab Biosimilar Sales by Type
  7. 4.2.1 Global Trastuzumab Biosimilar Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Trastuzumab Biosimilar Sales by Type (2021-2032)
  9. 4.2.3 Global Trastuzumab Biosimilar Sales Market Share by Type (2021-2032)
  10. 4.3 Global Trastuzumab Biosimilar Revenue by Type
  11. 4.3.1 Global Trastuzumab Biosimilar Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Trastuzumab Biosimilar Revenue by Type (2021-2032)
  13. 4.3.3 Global Trastuzumab Biosimilar Revenue Market Share by Type (2021-2032)
5 Trastuzumab Biosimilar Market by Application
  1. 5.1 Trastuzumab Biosimilar Application Introduction
  2. 5.1.1 Hospital Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.2 Global Trastuzumab Biosimilar Sales by Application
  5. 5.2.1 Global Trastuzumab Biosimilar Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Trastuzumab Biosimilar Sales by Application (2021-2032)
  7. 5.2.3 Global Trastuzumab Biosimilar Sales Market Share by Application (2021-2032)
  8. 5.3 Global Trastuzumab Biosimilar Revenue by Application
  9. 5.3.1 Global Trastuzumab Biosimilar Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Trastuzumab Biosimilar Revenue by Application (2021-2032)
  11. 5.3.3 Global Trastuzumab Biosimilar Revenue Market Share by Application (2021-2032)
6 Global Trastuzumab Biosimilar Sales by Region
  1. 6.1 Global Trastuzumab Biosimilar Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Trastuzumab Biosimilar Sales by Region (2021-2032)
  3. 6.2.1 Global Trastuzumab Biosimilar Sales by Region (2021-2026)
  4. 6.2.2 Global Trastuzumab Biosimilar Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Trastuzumab Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Trastuzumab Biosimilar Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Trastuzumab Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Trastuzumab Biosimilar Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Trastuzumab Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Trastuzumab Biosimilar Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Trastuzumab Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Trastuzumab Biosimilar Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Trastuzumab Biosimilar Revenue by Region
  1. 7.1 Global Trastuzumab Biosimilar Revenue by Region
  2. 7.1.1 Global Trastuzumab Biosimilar Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Trastuzumab Biosimilar Revenue by Region (2021-2026)
  4. 7.1.3 Global Trastuzumab Biosimilar Revenue by Region (2027-2032)
  5. 7.1.4 Global Trastuzumab Biosimilar Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Trastuzumab Biosimilar Revenue (2021-2032)
  8. 7.2.2 North America Trastuzumab Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Trastuzumab Biosimilar Revenue (2021-2032)
  11. 7.3.2 Europe Trastuzumab Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Trastuzumab Biosimilar Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Trastuzumab Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Trastuzumab Biosimilar Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Trastuzumab Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Mundipharma
  2. 8.1.1 Mundipharma Company Information
  3. 8.1.2 Mundipharma Business Overview
  4. 8.1.3 Mundipharma Trastuzumab Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Mundipharma Trastuzumab Biosimilar Product Portfolio
  6. 8.1.5 Mundipharma Recent Developments
  7. 8.2 Samsung Bioepis
  8. 8.2.1 Samsung Bioepis Company Information
  9. 8.2.2 Samsung Bioepis Business Overview
  10. 8.2.3 Samsung Bioepis Trastuzumab Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Samsung Bioepis Trastuzumab Biosimilar Product Portfolio
  12. 8.2.5 Samsung Bioepis Recent Developments
  13. 8.3 Amgen Inc.
  14. 8.3.1 Amgen Inc. Company Information
  15. 8.3.2 Amgen Inc. Business Overview
  16. 8.3.3 Amgen Inc. Trastuzumab Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Inc. Trastuzumab Biosimilar Product Portfolio
  18. 8.3.5 Amgen Inc. Recent Developments
  19. 8.4 Biocon Limited
  20. 8.4.1 Biocon Limited Company Information
  21. 8.4.2 Biocon Limited Business Overview
  22. 8.4.3 Biocon Limited Trastuzumab Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Biocon Limited Trastuzumab Biosimilar Product Portfolio
  24. 8.4.5 Biocon Limited Recent Developments
  25. 8.5 Henlius
  26. 8.5.1 Henlius Company Information
  27. 8.5.2 Henlius Business Overview
  28. 8.5.3 Henlius Trastuzumab Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Henlius Trastuzumab Biosimilar Product Portfolio
  30. 8.5.5 Henlius Recent Developments
  31. 8.6 Pfizer Inc
  32. 8.6.1 Pfizer Inc Company Information
  33. 8.6.2 Pfizer Inc Business Overview
  34. 8.6.3 Pfizer Inc Trastuzumab Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Inc Trastuzumab Biosimilar Product Portfolio
  36. 8.6.5 Pfizer Inc Recent Developments
  37. 8.7 Genentech
  38. 8.7.1 Genentech Company Information
  39. 8.7.2 Genentech Business Overview
  40. 8.7.3 Genentech Trastuzumab Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genentech Trastuzumab Biosimilar Product Portfolio
  42. 8.7.5 Genentech Recent Developments
  43. 8.8 Merck & Co.
  44. 8.8.1 Merck & Co. Company Information
  45. 8.8.2 Merck & Co. Business Overview
  46. 8.8.3 Merck & Co. Trastuzumab Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merck & Co. Trastuzumab Biosimilar Product Portfolio
  48. 8.8.5 Merck & Co. Recent Developments
  49. 8.9 Celltrion
  50. 8.9.1 Celltrion Company Information
  51. 8.9.2 Celltrion Business Overview
  52. 8.9.3 Celltrion Trastuzumab Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Celltrion Trastuzumab Biosimilar Product Portfolio
  54. 8.9.5 Celltrion Recent Developments
  55. 8.10 Teva Pharmaceutical
  56. 8.10.1 Teva Pharmaceutical Company Information
  57. 8.10.2 Teva Pharmaceutical Business Overview
  58. 8.10.3 Teva Pharmaceutical Trastuzumab Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceutical Trastuzumab Biosimilar Product Portfolio
  60. 8.10.5 Teva Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Trastuzumab Biosimilar Value Chain Analysis
  2. 9.1.1 Trastuzumab Biosimilar Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Trastuzumab Biosimilar Production Mode & Process
  6. 9.2 Trastuzumab Biosimilar Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Trastuzumab Biosimilar Distributors
  9. 9.2.3 Trastuzumab Biosimilar Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst